Skip to main content
Fig. 7 | BMC Ophthalmology

Fig. 7

From: Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

Fig. 7

Proportion of patients remaining on index treatment after the index date. †P-value for analysis of OTX-101 vs. CsA. The Day 360 P-value is statistically significant as based on a significance level of < 0.05. ‡P-value for analysis of OTX-101 vs. LFT. CsA, cyclosporine ophthalmic emulsion 0.05%; LFT, lifitegrast ophthalmic solution 5%; OTX-101, cyclosporine ophthalmic solution 0.09%

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us